{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:40:27Z","timestamp":1785735627359,"version":"3.56.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>This study aims to assess the safety profile of COVID-19 vaccines (mRNA and viral vector vaccines) in teenagers and young adults, as compared to Influenza and HPV vaccines, and to early data from Monkeypox vaccination in United States.<\/jats:p><jats:sec><jats:title>Methods<\/jats:title><jats:p>We downloaded data from the Vaccine Adverse Event Reporting System (VAERS) and collected the following Serious Adverse Events (SAEs) reported for COVID-19, Influenza, HPV and Monkeypox vaccines: deaths, life-threatening illnesses, disabilities, hospitalizations. We restricted our analysis to the age groups 12\u201317 and 18\u201349, and to the periods December 2020 to July 2022 for COVID-19 vaccines, 2010\u20132019 for Influenza vaccines, 2006\u20132019 for HPV vaccines, June 1, 2022 to November 15, 2022 for Monkeypox vaccine. Rates were calculated in each age and sex group, based on an estimation of the number of administered doses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among adolescents the total number of reported SAEs per million doses for, respectively, COVID-19, Influenza and HPV vaccines were 60.73, 2.96, 14.62. Among young adults the reported SAEs rates for, respectively, COVID-19, Influenza, Monkeypox vaccines were 101.91, 5.35, 11.14. Overall, the rates of reported SAEs were significantly higher for COVID-19, resulting in a rate 19.60-fold higher than Influenza vaccines (95% C.I. 18.80\u201320.44), 4.15-fold higher than HPV vaccines (95% C.I. 3.91\u20134.41) and 7.89-fold higher than Monkeypox vaccine (95% C.I. 3.95\u201315.78). Similar trends were observed in teenagers and young adults with higher Relative Risks for male adolescents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The study identified a risk of SAEs following COVID-19 vaccination which was markedly higher compared to Influenza vaccination and substantially higher compared to HPV vaccination, both for teenagers and young adults, with an increased risk for the male adolescents group. Initial, early data for Monkeypox vaccination point to significantly lower rates of reported SAEs compared to those for COVID-19 vaccines. In conclusion these results stress the need of further studies to explore the bases for the above differences and the importance of accurate harm-benefit analyses, especially for adolescent males, to inform the COVID-19 vaccination campaign.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1145645","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T04:36:35Z","timestamp":1686544595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A comparative analysis on serious adverse events reported for COVID-19 vaccines in adolescents and young adults"],"prefix":"10.3389","volume":"11","author":[{"given":"Beniamino","family":"Cappelletti-Montano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Demuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Laconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Musio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1016\/j.vaccine.2022.08.036","article-title":"Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults","volume":"40","author":"Fraiman","year":"2022","journal-title":"Vaccine"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"108449","DOI":"10.1136\/jme-2022-108449","article-title":"COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities","author":"Bardosh","year":"2022","journal-title":"J. Med. Ethics"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/014107689108400612","article-title":"Spontaneous adverse drug reaction reporting vs event monitoring: a comparison","volume":"84","author":"Fletcher","year":"1991","journal-title":"J R Soc Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"ref8","first-page":"10","article-title":"The complicated task of monitoring vaccine safety","volume":"112","author":"Ellenberg","year":"1997","journal-title":"Public Health Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1018785","DOI":"10.3389\/fneur.2022.1018785","article-title":"CNS inflammatory demyelinating events after COVID-19 vaccines: a case series and systematic review","volume":"13","author":"Rinaldi","year":"2022","journal-title":"Front Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e0278334","DOI":"10.1371\/journal.pone.0278334","article-title":"Post COVID-19 vaccination side effects and associated factors among vaccinated health care providers in Oromia region, Ethiopia in 2021","volume":"17","author":"Segni","year":"2022","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"921760","DOI":"10.3389\/fphar.2022.921760","article-title":"Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: gaining insight through the VAERS","volume":"13","author":"Yan","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.6002\/ect.2021.0","article-title":"Mandatory sanitary pass: is it justified?","volume":"20","author":"Barbari","year":"2022","journal-title":"Exp Clin Transplant"},{"key":"ref13","year":"2022"},{"key":"ref14","article-title":"SO2-D2.1.3 priority list of COVID-19 adverse events of special interest. 2021 October","author":"Law","year":"2021"},{"key":"ref15","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination\u2013updated recommendations of the advisory committee on immunization practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/encyclopedia2010028","article-title":"Adverse events profile of COVID-19 preventative strategies","volume":"2","author":"Ajmera","year":"2022","journal-title":"Encyclopedia"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"756633","DOI":"10.3389\/fpubh.2021.756633","article-title":"Frequency and associations of adverse reactions of COVID-19 vaccines reported to pharmacovigilance Systems in the European Union and the United States","volume":"9","author":"Montano","year":"2022","journal-title":"Front Public Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1111\/jcpt.13767","article-title":"Hearing disorder following COVID-19 vaccination: a pharmacovigilance analysis using the vaccine adverse event reporting system","volume":"47","author":"Chen","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1111\/bcp.15415","article-title":"VAERS-reported new-onset seizures following use of COVID-19 vaccinations as compared to influenza vaccinations","volume":"88","author":"Avasarala","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"952781","DOI":"10.3389\/fpubh.2022.952781","article-title":"Oral adverse events following COVID-19 vaccination: analysis of VAERS reports","volume":"10","author":"Riad","year":"2022","journal-title":"Front Public Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.33321\/cdi.2022.46.47","article-title":"Surveillance of adverse events following immunisation in Australia annual report, 2020","author":"Dey","year":"2018","journal-title":"Commun Dis Intell"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2014developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Disc"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/wrna.1189","article-title":"Messenger RNA-based vaccines: progress, challenges, applications","volume":"4","author":"Kramps","year":"2013","journal-title":"Wiley Interdiscipl Rev RNA"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"12542","DOI":"10.1074\/jbc.M310175200","article-title":"mRNA is an endogenous ligand for toll-like receptor 3","volume":"279","author":"Karik\u00f3","year":"2004","journal-title":"J Biol Chem"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"108480","DOI":"10.1016\/j.clim.2020.108480","article-title":"Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases","volume":"217","author":"Vojdani","year":"2020","journal-title":"Clin Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jhep.2021.09.031","article-title":"Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed","volume":"76","author":"Tun","year":"2022","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.molmed.2022.04.007","article-title":"Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis","volume":"28","author":"Trougakos","year":"2022","journal-title":"Trends Mol Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"927306","DOI":"10.3389\/fmicb.2022.927306","article-title":"Comprehensive review of the protein subunit vaccines against COVID-19","volume":"13","author":"Heidary","year":"2022","journal-title":"Front Microbiol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2021.04.019","article-title":"SARS-CoV-2 vaccines: lights and shadows","volume":"88","author":"Angeli","year":"2021","journal-title":"Eur J Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and gender differences in the outcomes of vaccination over the life course","volume":"33","author":"Flanagan","year":"2017","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2021.1669","article-title":"Gender differences in vaccine therapy: where are we in COVID-19 pandemic?","volume":"91","author":"Ciarambino","year":"2021","journal-title":"Monaldi Arch Chest Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect Dis"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1145645\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T04:36:39Z","timestamp":1686544599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1145645\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":33,"alternative-id":["10.3389\/fpubh.2023.1145645"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1145645","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"article-number":"1145645"}}